<DOC>
	<DOC>NCT02595983</DOC>
	<brief_summary>The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis, whose disease has continued to worsen after liver transplantation. Dosing has been discontinued; patients are being followed-up for safety.</brief_summary>
	<brief_title>The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies, Familial</mesh_term>
	<criteria>Diagnosis of FAP (familial amyloidotic polyneuropathy) with documented TTR mutation Received an orthotopic liver transplant ≥12 months before the date of informed consent An increase in polyneuropathy disability (PND) score posttransplant Polyneuropathy Disability score of ≤3b New York Heart Association (NYHA) classification of &gt;2 Other known causes of sensorimotor or autonomic neuropathy (eg, autoimmune disease)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloidotic Polyneuropathy</keyword>
	<keyword>ATTR Amyloidosis</keyword>
	<keyword>Orthotopic Liver Transplant</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>